生物科技和DualityBio报告了对HER2阳性复发子宫内膜癌的有效抗体-药物结合剂. BioNTech and DualityBio report effective antibody-drug conjugate for HER2-positive recurrent endometrial cancer.

据BioNTech和DualityBio报告,他们的抗体-药物结合剂trastuzumab pamirtecan在HER2阳性复发子宫内膜癌患者中显示出显著的疗效,这标志着该组病人潜在的新治疗选择. BioNTech and DualityBio report their antibody-drug conjugate trastuzumab pamirtecan showed meaningful efficacy in patients with HER2-positive recurrent endometrial cancer, marking a potential new treatment option for this patient group.